

DFN



PATENT
Customer No. 22,852
Attorney Docket No. 10525.0015-00000

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Takanori MATSUO et al.) Group Art Unit: 1644
)
Application No.: 10/534,486) Examiner: Gerald R. EWOLDT
)
Filed: May 11, 2005)
)
For: SCREENING METHOD) Confirmation No. 7810

MAIL STOP AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RESPONSE TO RESTRICTION REQUIREMENT

Applicants now respond to the Restriction Requirement mailed September 27, 2007. The Examiner required restriction to one of the following groups of claims under the unity of invention practice under PCT Rule 13.1:

Group I: claim 5, allegedly "drawn to a method of screening comprising quantifying protein."

Group II: claims 9 and 13-18, allegedly "drawn to a method of screening comprising quantifying gene expression."

Group III: claims 7 and 11, allegedly "drawn to a method of screening comprising quantifying protein activity."

Group IV: claim 6, allegedly "drawn to a kit comprising a cell and an antibody."

Group V: claims 6, 12, and 19, allegedly "drawn to a kit comprising a cell and a polynucleotide."

Group VI: claim 6, allegedly "drawn to a kit comprising a cell and a transcription factor."

Group VII: claim 8, allegedly "drawn to a kit comprising a protein, a polynucleotide, and a transcription factor."

Group VIII: claim 10, allegedly "drawn to a kit comprising a cell, a protein, and a polynucleotide."

Group IX: claims 20-22, 34, and 35, allegedly "drawn to a therapeutic method comprising administering an antibody."

Group X: claims 23-25, allegedly "drawn to a therapeutic method comprising administering a polynucleotide."

Group XI: claims 26-28, allegedly "drawn to a diagnostic method employing an antibody."

Group XII: claims 29-31, allegedly "drawn to a diagnostic method employing a polynucleotide."

Applicants elect Group II, claims 9 and 13-18, without traverse. Applicants do note, however, that the Examiner has stated that claims 1-4 link inventions I-III and that upon allowance of the linking claims, the restriction requirement as to the linked inventions shall be withdrawn.

Please grant any extensions of time required to enter this response and charge any additional required fees to Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,
GARRETT & DUNNER, L.L.P.

Dated: October 19, 2007

By:



Yuko Soneoka
Reg. No. 60,018
Customer No. 22,852